MCID: PRM226
MIFTS: 51

Primary Central Nervous System Lymphoma

Categories: Rare diseases, Neuronal diseases, Blood diseases, Immune diseases, Cancer diseases

Aliases & Classifications for Primary Central Nervous System Lymphoma

MalaCards integrated aliases for Primary Central Nervous System Lymphoma:

Name: Primary Central Nervous System Lymphoma 53 59 55 73
Primary Brain Lymphoma 53 59
Primary Cns Lymphoma 53 59
Pcnsl 53 59
Primary Cerebral Lymphoma 73
Primary Lymphoma, Cns 53

Characteristics:

Orphanet epidemiological data:

59
primary central nervous system lymphoma
Inheritance: Not applicable;

Classifications:



External Ids:

Orphanet 59 ORPHA46135
ICD10 via Orphanet 34 C83.3
UMLS via Orphanet 74 C0240803 C0280803

Summaries for Primary Central Nervous System Lymphoma

NIH Rare Diseases : 53 Primary central nervous system lymphoma (primary CNS lymphoma) is a rare form of non-Hodgkin lymphoma in which cancerous cells develop in the lymph tissue of the brain and/or spinal cord. Because the eye is so close to the brain, primary CNS lymphoma can also start in the eye (called ocular lymphoma). The signs and symptoms vary based on which parts of the central nervous system are affected, but may include nausea and vomiting; seizures; headaches; arm or leg weakness; confusion; double vision and/or hearing loss. The exact underlying cause of primary CNS lymphoma is poorly understood; however, people with a weakened immune system (such as those with acquired immunodeficiency syndrome) or who have had an organ transplant appear to have an increased risk of developing the condition. Treatment varies based on the severity of the condition and location of the cancerous cells.

MalaCards based summary : Primary Central Nervous System Lymphoma, also known as primary brain lymphoma, is related to intraocular lymphoma and lymphoma. An important gene associated with Primary Central Nervous System Lymphoma is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are NF-kappaB Signaling and DNA Damage Response (only ATM dependent). The drugs Methotrexate and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and b cells, and related phenotypes are cellular and hematopoietic system

Wikipedia : 76 A primary central nervous system lymphoma (PCNSL), also known as microglioma and primary brain lymphoma,... more...

Related Diseases for Primary Central Nervous System Lymphoma

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Primary Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 intraocular lymphoma 31.6 BCL6 CXCL12 PAX5
2 lymphoma 31.3 BCL2 BCL6 PAX5
3 central nervous system lymphoma 30.3 BCL6 CDKN2A CXCL12 MGMT MYD88
4 lymphoma, hodgkin, classic 30.0 BCL6 PAX5
5 b-cell lymphomas 28.5 BCL2 BCL6 CDKN2A PAX5
6 lymphoma, non-hodgkin, familial 28.4 BCL2 BCL6 CXCL12 PAX5
7 leukemia, chronic lymphocytic 27.6 BCL2 BCL6 CXCL12 IGHM PAX5
8 testicular lymphoma 10.5 BCL6 MYD88
9 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.5 BCL2 BCL6
10 nodal marginal zone b-cell lymphoma 10.5 BCL2 BCL6
11 follicular lymphoma 1 10.5 BCL2 BCL6
12 intravascular large b-cell lymphoma 10.5 BCL2 BCL6
13 primary mediastinal large b-cell lymphoma 10.5 BCL2 BCL6
14 human herpesvirus 8 10.4 BCL2 BCL6
15 gastric lymphoma 10.4 BCL2 BCL6
16 nodular lymphocyte predominant hodgkin lymphoma 10.3 BCL6 PAX5
17 glioblastoma 10.3
18 composite lymphoma 10.3 BCL6 PAX5
19 multicentric castleman disease 10.3 BCL6 PAX5
20 mediastinal malignant lymphoma 10.2 BCL6 PAX5
21 lung lymphoma 10.2 BCL6 PAX5
22 meningitis 10.2
23 splenic marginal zone lymphoma 10.1 BCL6 PAX5
24 hepatitis 10.1
25 endotheliitis 10.1
26 encephalitis 10.1
27 glioma 10.1
28 multiple sclerosis 10.1
29 marginal zone b-cell lymphoma 10.1 BCL2 BCL6 MYD88
30 reticulosarcoma 10.1 BCL6 PAX5
31 hepatitis b 10.1
32 lymphomatous meningitis 10.1
33 aging 10.1
34 acquired immunodeficiency syndrome 10.1
35 primary cutaneous diffuse large b-cell lymphoma, leg type 10.0 CDKN2A MYD88
36 autoimmune lymphoproliferative syndrome, type v 10.0
37 arthritis 10.0
38 diffuse large b-cell lymphoma 10.0
39 rheumatoid arthritis 10.0
40 richter's syndrome 10.0
41 colon lymphoma 10.0 BCL6 CDKN2A
42 plasmablastic lymphoma 9.9 BCL6 CDKN2A
43 lymphoma, mucosa-associated lymphoid type 9.9 BCL2 BCL6
44 blastic plasmacytoid dendritic cell 9.9 CDKN2A MYD88
45 anaplastic oligodendroglioma 9.9 CDKN2A MGMT
46 suppressor of tumorigenicity 3 9.9 BCL2 CDKN2A
47 anal squamous cell carcinoma 9.9 CDKN2A MGMT
48 breast giant fibroadenoma 9.8 CDKN2A MGMT
49 histoplasmosis 9.8
50 lupus erythematosus 9.8

Graphical network of the top 20 diseases related to Primary Central Nervous System Lymphoma:



Diseases related to Primary Central Nervous System Lymphoma

Symptoms & Phenotypes for Primary Central Nervous System Lymphoma

MGI Mouse Phenotypes related to Primary Central Nervous System Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.88 CXCL12 BCL2 MYD88 BCL6 PAX5 CDKN2A
2 hematopoietic system MP:0005397 9.85 CXCL12 BCL2 MYD88 BCL6 PAX5 CDKN2A
3 immune system MP:0005387 9.8 CXCL12 BCL2 MYD88 BCL6 PAX5 CDKN2A
4 mortality/aging MP:0010768 9.8 CXCL12 MGMT BCL2 MYD88 BCL6 PAX5
5 neoplasm MP:0002006 9.55 MGMT MYD88 BCL2 PAX5 CDKN2A
6 no phenotypic analysis MP:0003012 9.35 CXCL12 MGMT MYD88 BCL6 CDKN2A
7 reproductive system MP:0005389 9.02 CDKN2A CXCL12 BCL2 MYD88 BCL6

Drugs & Therapeutics for Primary Central Nervous System Lymphoma

Drugs for Primary Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
2
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
4
Teniposide Approved Phase 4 29767-20-2 34698
5
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
7
Fotemustine Experimental, Investigational Phase 4
8 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
20 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
22 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23
rituximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
24
Etoposide Approved Phase 3,Phase 1,Phase 2,Not Applicable 33419-42-0 36462
25
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
26
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
27
Ofloxacin Approved Phase 3 82419-36-1 4583
28
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 85622-93-1 5394
29
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
30
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
31
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
32
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
33
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
34
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
35
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
36
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
37
Thiotepa Approved, Investigational Phase 3,Phase 2 52-24-4 5453
38
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
39
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
40
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
41
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
42
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
43
Dalteparin Approved Phase 3 9005-49-6
44
Carmustine Approved, Investigational Phase 3,Phase 2 154-93-8 2578
45
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
46
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
47
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 68538-85-2
48
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
49 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
50 Analgesics Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
2 Treatment of Primary CNS Lymphoma Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
6 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
10 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
12 Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Recruiting NCT02836158 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
13 Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Recruiting NCT02313389 Phase 3 Rituximab, Methotrexate, Temozolomide
14 High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma Recruiting NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
15 Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Enrolling by invitation NCT02657785 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
16 a Phase II Study in Primary Central Nervous System Lymphoma Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
17 Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
18 Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma Unknown status NCT00942747 Phase 2 temsirolimus
19 Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
20 Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Unknown status NCT00503594 Phase 2 Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
21 Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
22 Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma Unknown status NCT00989352 Phase 2 Methotrexate;Lomustine;Procarbazine;Rituximab
23 Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
24 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
25 PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed NCT02669511 Phase 2 PQR309
26 Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma Completed NCT00193973 Phase 2 Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
27 Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
28 Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed NCT02301364 Phase 2 Buparlisib (BKM120)
29 Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma Completed NCT00210314 Phase 2 high dose methotrexate;high dose cytarabine
30 Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
31 Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
32 Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Completed NCT00068250 Phase 1, Phase 2 rituximab;methotrexate;temozolomide 100 mg/m^2;temozolomide 150 mg/m^2;temozolomide 200 mg/m^2;post-radiation therapy temozolomide
33 Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00000801 Phase 2 Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone
34 Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS Completed NCT00002940 Phase 2 hydroxyurea
35 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma Completed NCT00003061 Phase 2 cytarabine;methotrexate
36 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Completed NCT01011920 Phase 2 Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
37 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00098774 Phase 2 cytarabine;etoposide;leucovorin calcium;methotrexate;temozolomide
38 Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00045539 Phase 2 leucovorin calcium;methotrexate;thiotepa
39 High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Completed NCT01083342 Phase 2 MTX, MVD, VIA
40 Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00727831 Phase 1, Phase 2 glucarpidase;leucovorin calcium;methotrexate
41 High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Completed NCT01182415 Phase 2 High-dose chemotherapy
42 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma Completed NCT00003632 Phase 2 carmustine;cytarabine;etoposide;melphalan;methotrexate
43 Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma Completed NCT00248534 Phase 2 methylprednisolone;temozolomide
44 A Study for Patients With Non-Hodgkin's Lymphomas Completed NCT00542919 Phase 2 enzastaurin
45 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
46 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
47 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Completed NCT00005811 Phase 2 topotecan hydrochloride
48 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
49 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
50 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2

Search NIH Clinical Center for Primary Central Nervous System Lymphoma

Genetic Tests for Primary Central Nervous System Lymphoma

Anatomical Context for Primary Central Nervous System Lymphoma

MalaCards organs/tissues related to Primary Central Nervous System Lymphoma:

41
Brain, Eye, B Cells, Spinal Cord, Liver, Bone, Bone Marrow

Publications for Primary Central Nervous System Lymphoma

Articles related to Primary Central Nervous System Lymphoma:

(show top 50) (show all 615)
# Title Authors Year
1
Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013). ( 29796994 )
2018
2
Primary central nervous system lymphoma at the cerebellopontine angle mimicking a trigeminal schwannoma: A unique case report and literature review. ( 29656000 )
2018
3
Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis. ( 29447417 )
2018
4
Significance of treatment response when managing patients with primary central nervous system lymphoma. ( 29966463 )
2018
5
Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation. ( 29361117 )
2018
6
Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. ( 29879076 )
2018
7
Machine Learning-based Texture Analysis of Contrast-enhanced MR Imaging to Differentiate between Glioblastoma and Primary Central Nervous System Lymphoma. ( 29769456 )
2018
8
MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. ( 29258950 )
2018
9
Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. ( 29633883 )
2018
10
Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma. ( 29330078 )
2018
11
Stereotactic brachytherapy with iodine-125 seeds plus temozolomide induce complete and durable remission in a patient with recurrent primary central nervous system lymphoma. ( 29960094 )
2018
12
Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma. ( 29331383 )
2018
13
Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation. ( 29438500 )
2018
14
B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma. ( 29871654 )
2018
15
Spinal primary central nervous system lymphoma: Case report and literature review. ( 29429785 )
2018
16
Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents? ( 29804159 )
2018
17
Primary central nervous system lymphoma presenting as growing intracerebral hemorrhage. ( 29803066 )
2018
18
Isolated acute vestibular syndrome due to presumed primary central nervous system lymphoma involving the dorsal medulla. ( 29936666 )
2018
19
Craniotomy and Survival for Primary Central Nervous System Lymphoma. ( 29660011 )
2018
20
Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. ( 29741421 )
2018
21
Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. ( 29323247 )
2018
22
Identification of novel recurrent ETV6-IGH fusions in primary central nervous system lymphoma. ( 29432597 )
2018
23
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). ( 29416652 )
2018
24
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma. ( 29662865 )
2018
25
<sup>18</sup>F-FDG PET/CT in immunocompetent patients with primary central nervous system lymphoma: Differentiation from glioblastoma and correlation with DWI. ( 29857862 )
2018
26
A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique. ( 29744624 )
2018
27
A case of primary central nervous system lymphoma arising at the site of remote herpes encephalitis. ( 29382621 )
2018
28
Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities. ( 29891112 )
2018
29
Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. ( 29937999 )
2018
30
Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma. ( 29877882 )
2018
31
Presence of apoptosis distinguishes primary central nervous system lymphoma from glioblastoma during intraoperative consultation. ( 29336777 )
2018
32
Radiotherapy as an alternative treatment option for primary central nervous system lymphoma patients who are noncandidates for chemotherapy. ( 29290994 )
2017
33
Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. ( 28982883 )
2017
34
Comparison between Glioblastoma and Primary Central Nervous System Lymphoma Using MR Image-based Texture Analysis. ( 28638001 )
2017
35
Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. ( 28084866 )
2017
36
Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. ( 28805292 )
2017
37
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. ( 28521029 )
2017
38
Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding. ( 29299134 )
2017
39
Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma. ( 28806317 )
2017
40
Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. ( 28058506 )
2017
41
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience. ( 28633037 )
2017
42
Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. ( 29213063 )
2017
43
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. ( 28881844 )
2017
44
Relapsed or refractory primary central nervous system lymphoma radiosurgery: Report of the International Gamma Knife Research Foundation. ( 29296450 )
2017
45
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission. ( 28542721 )
2017
46
Advances in the management of primary central nervous system lymphoma. ( 28949937 )
2017
47
Advances in Pathobiology of Primary Central Nervous System Lymphoma. ( 28776551 )
2017
48
High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. ( 28581466 )
2017
49
Clinicopathological Features and Outcomes in Primary Central Nervous System Lymphoma: A 10-year Experience. ( 29333016 )
2017
50
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. ( 28012348 )
2017

Variations for Primary Central Nervous System Lymphoma

Cosmic variations for Primary Central Nervous System Lymphoma:

9
(show all 34)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10656 TP53 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.742C>T p.R248W 17:7674221-7674221 13
2 COSM43448 TNFAIP3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2273C>G p.P758R 6:137881219-137881219 13
3 COSM5878666 TET2 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.4034A>C p.Y1345S 4:105261838-105261838 13
4 COSM4440697 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1255T>A p.S419T 3:177033132-177033132 13
5 COSM4440707 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.596G>A p.S199N 3:177050103-177050103 13
6 COSM4440703 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1376G>A p.S459N 3:177033011-177033011 13
7 COSM4440696 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1256C>T p.S419F 3:177033131-177033131 13
8 COSM4440698 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1335G>T p.V445V 3:177033052-177033052 13
9 COSM4440709 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.148A>T p.I50F 3:177053829-177053829 13
10 COSM4440712 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.230C>T p.P77L 3:177051701-177051701 13
11 COSM4440706 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.637C>A p.H213N 3:177050062-177050062 13
12 COSM4440705 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1274G>T p.R425M 3:177033113-177033113 13
13 COSM4440713 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.229C>A p.P77T 3:177051702-177051702 13
14 COSM4440710 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.70T>C p.S24P 3:177053907-177053907 13
15 COSM4440704 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1336T>G p.Y446D 3:177033051-177033051 13
16 COSM4440708 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.458G>A p.G153E 3:177050580-177050580 13
17 COSM4440695 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1261G>C p.D421H 3:177033126-177033126 13
18 COSM1716590 STAT5B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1924A>C p.N642H 17:42207711-42207711 13
19 COSM1155745 STAT3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1981G>C p.D661H 17:42322402-42322402 13
20 COSM97163 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.556+1G>C p.? 6:106099553-106099553 13
21 COSM97162 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.183G>A p.E62fs 6:106088449-106088449 13
22 COSM85940 MYD88 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.794T>C p.L265P 3:38141150-38141150 13
23 COSM517 KRAS haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.34G>A p.G12S 12:25245351-25245351 13
24 COSM306058 JAK3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1533G>T p.M511I 19:17838299-17838299 13
25 COSM5878665 DNMT3A haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2207G>T p.R736L 2:25240417-25240417 13
26 COSM144393 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>A p.Y196N 17:63929439-63929439 13
27 COSM220733 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>C p.Y196S 17:63929438-63929438 13
28 COSM1737939 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>G p.Y196D 17:63929439-63929439 13
29 COSM220734 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>C p.Y196H 17:63929439-63929439 13
30 COSM220736 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>G p.Y196C 17:63929438-63929438 13
31 COSM5045028 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.591G>C p.E197D 17:63929434-63929434 13
32 COSM43455 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>C p.F115L 7:2945834-2945834 13
33 COSM43452 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>A p.F115I 7:2945834-2945834 13
34 COSM43451 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1010G>A p.R337Q 7:2938686-2938686 13

Copy number variations for Primary Central Nervous System Lymphoma from CNVD:

7 (show top 50) (show all 54)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13396 1 1 2300000 Gain Primary central nervous system lymphoma
2 40586 10 130500000 135374737 Gain Primary central nervous system lymphoma
3 48335 11 1 2800000 Gain Primary central nervous system lymphoma
4 50189 11 115400000 120700000 Gain Primary central nervous system lymphoma
5 57101 11 63100000 67100000 Gain Primary central nervous system lymphoma
6 81492 14 103000000 106368585 Gain Primary central nervous system lymphoma
7 81496 14 103000000 106368585 Loss Primary central nervous system lymphoma
8 94763 15 70400000 73100000 Gain Primary central nervous system lymphoma
9 97352 16 1 6300000 Gain Primary central nervous system lymphoma
10 99609 16 27600000 34400000 Gain Primary central nervous system lymphoma
11 106267 16 87200000 88827254 Gain Primary central nervous system lymphoma
12 106863 17 1 3600000 Gain P2RX5 Primary central nervous system lymphoma
13 106864 17 1 3600000 Gain TMEM93 Primary central nervous system lymphoma
14 117583 17 72900000 78774742 Gain Primary central nervous system lymphoma
15 124164 19 1 6900000 Gain Primary central nervous system lymphoma
16 128872 19 43400000 47800000 Gain Primary central nervous system lymphoma
17 130166 19 47800000 57600000 Gain Primary central nervous system lymphoma
18 132108 19 57600000 63811651 Gain Primary central nervous system lymphoma
19 155738 20 57900000 62435964 Gain Primary central nervous system lymphoma
20 159204 21 41400000 46944323 Gain Primary central nervous system lymphoma
21 162471 22 21800000 24300000 Loss Primary central nervous system lymphoma
22 165691 22 48200000 49691432 Gain IL17REL Primary central nervous system lymphoma
23 165692 22 48200000 49691432 Gain MLC1 Primary central nervous system lymphoma
24 168173 3 127700000 131500000 Gain Primary central nervous system lymphoma
25 168662 3 131500000 135700000 Gain Primary central nervous system lymphoma
26 168981 3 1357001 1525502 Deletion TPO Primary central nervous system lymphoma
27 173428 3 193800000 199501827 Gain Primary central nervous system lymphoma
28 180220 4 101538006 101658202 Deletion EMCN Primary central nervous system lymphoma
29 189173 4 71126403 71135557 Deletion C4orf7 Primary central nervous system lymphoma
30 189355 4 73116384 73237614 Deletion NPFFR2 Primary central nervous system lymphoma
31 199429 5 38881884 38970159 Deletion OSMR Primary central nervous system lymphoma
32 203980 6 104800000 113900000 Loss Primary central nervous system lymphoma
33 204682 6 113900000 118600000 Loss Primary central nervous system lymphoma
34 205017 6 118600000 130400000 Loss Primary central nervous system lymphoma
35 207626 6 159510416 159613130 Deletion FNDC1 Primary central nervous system lymphoma
36 207757 6 160900000 164400000 Loss Primary central nervous system lymphoma
37 211018 6 31900000 33600000 Loss Primary central nervous system lymphoma
38 215228 6 73300000 139100000 Loss Primary central nervous system lymphoma
39 215399 6 75850761 75972343 Deletion COL12A1 Primary central nervous system lymphoma
40 215419 6 75900000 87500000 Loss Primary central nervous system lymphoma
41 215890 6 82700000 145700000 Loss Primary central nervous system lymphoma
42 216158 6 87500000 92100000 Loss Primary central nervous system lymphoma
43 216419 6 92100000 104800000 Loss Primary central nervous system lymphoma
44 217057 7 1 2100000 Gain Primary central nervous system lymphoma
45 221886 7 147500000 152200000 Gain Primary central nervous system lymphoma
46 227727 7 71800000 77400000 Gain Primary central nervous system lymphoma
47 230089 7 97900000 104400000 Gain Primary central nervous system lymphoma
48 233710 8 12700000 19100000 Loss Primary central nervous system lymphoma
49 234942 8 140000000 146274826 Gain Primary central nervous system lymphoma
50 236937 8 19100000 23400000 Loss Primary central nervous system lymphoma

Expression for Primary Central Nervous System Lymphoma

Search GEO for disease gene expression data for Primary Central Nervous System Lymphoma.

Pathways for Primary Central Nervous System Lymphoma

GO Terms for Primary Central Nervous System Lymphoma

Biological processes related to Primary Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.61 BCL2 BCL6 MYD88
2 B cell differentiation GO:0030183 9.48 BCL2 BCL6
3 humoral immune response GO:0006959 9.46 BCL2 PAX5
4 positive regulation of B cell proliferation GO:0030890 9.4 BCL2 BCL6
5 response to radiation GO:0009314 9.37 BCL2 CXCL12
6 regulation of calcium ion transport GO:0051924 9.32 BCL2 CXCL12
7 apoptotic mitochondrial changes GO:0008637 9.26 BCL2 CDKN2A
8 negative regulation of apoptotic process GO:0043066 9.26 BCL2 BCL6 MGMT MYD88
9 negative regulation of cell-matrix adhesion GO:0001953 9.16 BCL6 CDKN2A
10 negative regulation of cell growth GO:0030308 8.8 BCL2 BCL6 CDKN2A

Sources for Primary Central Nervous System Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....